VYGR Voyager Therapeutics, Inc.

10.60
+0  (1%)
Previous Close 10.45
Open 10.40
Price To book 1.97
Market Cap 284.59M
Shares 26,848,000
Volume 137,334
Short Ratio 13.14
Av. Daily Volume 95,102

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b trial onoging. Interim data released December 7, 2016. Cohort 3 data due mid-2017. Placebo-controlled trial to commence 4Q 2017.
VY-AADC01
Advanced Parkinson’s disease

Latest News

  1. Voyager Therapeutics Announces Additional Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease
  2. 4 Sell-Ranked Drug Stocks Investors Should Avoid Ahead of Earnings
  3. Voyager Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : VYGR-US : April 11, 2017
  4. ETFs with exposure to Voyager Therapeutics, Inc. : April 5, 2017
  5. Voyager Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : VYGR-US : March 28, 2017
  6. Voyager Therapeutics, Inc. :VYGR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  7. Edited Transcript of VYGR earnings conference call or presentation 15-Mar-17 12:30pm GMT
  8. Voyager Therapeutics reports 4Q loss
  9. Voyager Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Corporate Highlights
  10. Voyager Therapeutics to Host Fourth Quarter and Full Year 2016 Financial Results Conference call
  11. Voyager Therapeutics Supports Rare Disease Day® and Global Movement to Raise Awareness for Rare Diseases
  12. Voyager Therapeutics Announces Lead Clinical Candidate Selection for Monogenic Form of Amyotrophic Lateral Sclerosis (ALS)
  13. Voyager Therapeutics to Attend Upcoming Investor Conferences
  14. MRI Interventions, Inc. Announces Year-End Update, Including 2016 Fourth Quarter and Full Year Revenues
  15. Voyager Therapeutics (VYGR) Sees Hammer Chart Pattern: Time to Buy?
  16. Tuesday’s Biggest Biotech and Pharma Moves